Martínez FJS, Jiménez RMB, García CM, et al. - Researchers conducted this multicentre, randomised, double‐blind, placebo‐controlled clinical trial to test the safety and effectiveness of immunotherapy with an allergen extract of glutaraldehyde‐polymerised Phleum pratense, administered intradermally, in patients with rhinoconjunctivitis sensitized to grass pollen. The sample consisted of patients aged 12 to 65 years with rhinitis or rhinoconjunctivitis, with or without asthma, due to grass pollen allergy. Study participants were divided into three groups and obtained a total of 6 doses in a weekly interval, of either placebo; 0.03 μg or 0.06 μg of protein per dose of Phleum pratense allergoid. It has been shown that intradermal immunotherapy with P. pratense allergoid is effective and safe, reduces combined symptoms and medication consumption score, improves tolerance to the conjunctival provocation test and reduces IgE levels.